Biological age reversal, epigenetic clocks, senolytics, and anti-aging interventions
1,811 articles
China's first standardized longevity medicine curriculum trains doctors in aging biology, cardiometabolic prevention, and AI-assisted care.
Researchers show that enhancing thymic epithelial cell activity in aged mice rebuilds naïve T-cell populations and dramatically improves survival after infection.
A comprehensive review deconstructs the thymic microenvironment using single-cell technologies, from embryonic formation through age-related involution.
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
A monoclonal antibody targeting muscle-wasting pathways shows promise countering sarcopenia, inclusion body myositis, and GLP-1-induced lean mass loss.
Once considered an aging disease, sarcopenia now threatens children too — raising long-term metabolic and cardiovascular risks.
A novel NMN-delivering hydrogel microsphere targets mitochondria in muscle cells, reducing senescence and offering a new treatment path for sarcopenia.
Researchers identify LAMP1 on the cell surface as a reliable senescence biomarker, rising with age and in fibrotic lungs, enabling targeted senolytic therapy.
A comprehensive 2025 review maps how stress-cytokine GDF15 drives obesity, diabetes, heart failure, and aging—and how to target it therapeutically.
Podocyte FFAR4 deficiency drives kidney aging and glomerular disease via senescence and lipid toxicity; fish oil and TUG891 reverse damage.
Exendin-4 (a GLP-1R agonist like semaglutide) rejuvenates senescent macrophages after spinal cord injury, restoring debris clearance and promoting nerve repair.
A deep-learning analysis of 3,476 patients shows thymic health measured from routine CT scans strongly predicts immunotherapy outcomes across cancer types.
